

## DAFTAR PUSTAKA

1. Tanaka Y. Systemic lupus erythematosus. *Best Pract Res Clin Rheumatol*. 2022;36(4):1–11.
2. Qiu W, Yu T, Deng G-M. The role of organ-deposited IgG in the pathogenesis of multi-organ and tissue damage in systemic lupus erythematosus. *Front Immunol*. 2022;13(10):1–7.
3. Accapezzato D, Caccavale R, Paroli MP, Gioia C, Nguyen BL, Spadea L, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus. *Int J Mol Sci*. 2023;24(7):1–23.
4. Zhang L, Lu W, Yan D, Liu Z, Xue L. Systemic lupus erythematosus risk probability index: Ready for routine use? Results from a Chinese cohort. *Lupus Sci Med*. 2023;10(2):1–6.
5. Lupu VV, Butnariu LI, Fotea S, Morariu ID, Badescu MC, Starcea IM, et al. The disease with a thousand faces and the human microbiome—A physiopathogenic intercorrelation in pediatric practice. *Nutrients*. 2023;15(15):1–18.
6. Kumar RR, Jha S, Dhooria A, Dhir V. Butterfly rash: Hallmark of lupus. *QJM*. 2019;112(11):877–7.
7. Tanzilia MF, Tambunan BA, Dewi DNSS. Tinjauan Pustaka: Patogenesis dan diagnosis sistemik lupus eritomatosis. *Syifa' Med J*. 2021;11(2):139–64.
8. Darma NAP, Saturti TIA, Kurniari PK. Karakteristik manifestasi klinis pasien sistemik lupus eritematosus di Poliklinik Rematologi RSUP Sanglah periode Juni – September 2018. *E-J Med Udayana*. 2020;9(5):29–34.
9. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. *Ann Rheum Dis*. 2023;82(3):351–6.
10. Esfandiari F, Pratama SA, Panonsih RN, Roselen RE. Hubungan faktor usia dengan kelelahan pada pasien systemic lupus erythematosus (SLE) di komunitas Lampung tahun 2019. *JurAlumni*. 2020;4(4):249–56.
11. Hikmah Z, Endaryanto A, Gede Ugrasena I. Systemic lupus erythematosus organ manifestation and disease activity in children based on Mexican systemic lupus erythematosus disease activity index score at East Java, Indonesia. *Indian J Rheumatol*. 2021;16(4):408–14.
12. Kasjmir YI, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H, et al. Rekomendasi diagnosis dan pengelolaan lupus erimatosus sistemik. Jakarta: Perhimpunan Reumatologi Indonesia; 2011.

13. Zeraati AA, Shariati Z, Masinaee M, Azarfar A, Samadi K, Moradi E, et al. Correlation of systemic lupus erythematosus disease activity (SLEDAI) with serum level of albumin in lupus patients. *Immunopathol Persa*. 2021;10(10):1–4.
14. Anjani H, Sumardiono, Triono A. Correlation between albumin level in blood and severity of systemic lupus erythematosus in children. [Skripsi]. [Yogyakarta]: Universitas Gadjah Mada; 2020
15. Ene CD, Georgescu SR, Tampa M, Matei C, Mitran CI, Mitran MI, et al. Cellular response against oxidative stress, a novel insight into lupus nephritis pathogenesis. *J Pers Med*. 2021;11(8):1–18.
16. Sui M, Jia X, Yu C, Guo X, Liu X, Ji Y, et al. Clinical immunology Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: A prospective study. *Cent Eur J Immunol*. 2014;39(2):243–52.
17. Xanthouli P, Mühleisen H, Briem S, Weis D, Fiehn C. Enteraler proteinverlust als ursache einer schweren hypoalbuminämie bei systemischem lupus erythematoses. *Z Rheumatol*. 2011;70(3):239–44.
18. Chen Z, Li M-T, Xu D, Yang H, Li J, Zhao J-L, et al. Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center. *PLoS One*. 2014;9(12):1–14.
19. Idborg H, Eketjäll S, Pettersson S, Gustafsson JT, Zickert A, Kvarnström M, et al. TNF- $\alpha$  and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. *Lupus Sci Med*. 2018;5(1):1–11.
20. Bell CF, Ajmera MR, Meyers J. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. *Lupus Sci Med*. 2022;31(2):202–11.
21. Cooper EE, Pisano CE, Shapiro SC. Cutaneous manifestations of “lupus”: Systemic lupus erythematosus and beyond. *Int J Rheumatol*. 2021;2021(5):1–19.
22. Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New diagnostic and therapeutic approaches. *Annu Rev Med*. 2023;74(7):339–52.
23. Saletra A, Olesińska M. Quality of life in systemic lupus erythematosus and its measurement. *Reumatologia*. 2018;56(1):45–54.
24. Santos A, Kure C, Sanchez C, Gross P. The diagnostic dilemma of “the great imitator”: Heart and cerebral involvement of lupus manifesting as bilateral upper and lower extremity weakness. *Case Rep Rheumatol*. 2023;2023(10):1–4.

25. Demkova K, Morris DL, Vyse TJ. Genetics of SLE: does this explain susceptibility and severity across racial groups?. *Rheumatology (Oxford)*. 2023;62(11):15–21.
26. Pan Q, Chen X, Liao S, Chen X, Zhao C, Xu Y-Z, et al. Updated advances of linking psychosocial factors and sex hormones with systemic lupus erythematosus susceptibility and development. *PeerJ*. 2019;7(6):1–17.
27. Pan L, Lu M-P, Wang J-H, Xu M, Yang S-R. Immunological pathogenesis and treatment of systemic lupus erythematosus. *World J Pediatr*. 2020;16(1):19–30.
28. Wolf SJ, Estadt SN, Theros J, Moore T, Ellis J, Liu J, et al. Ultraviolet light induces increased T cell activation in lupus-prone mice via type I IFN-dependent inhibition of T regulatory cells. *J Autoimmun*. 2019;103(6):1–8.
29. Cozier YC, Barbhaiya M, Castro-Webb N, Conte C, Tedeschi SK, Leatherwood C, et al. Relationship of cigarette smoking and alcohol consumption to incidence of systemic lupus erythematosus in a prospective cohort study of black women. *Arthritis Care Res (Hoboken)*. 2019;71(5):671–7.
30. Jog NR, James JA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. *Front Immunol*. 2021;11(2):1–11.
31. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. *Curr Opin Rheumatol*. 2018;30(5):490-7.
32. Tenbrock K, Rauen T. T cell dysregulation in SLE. *Clin Immunol*. 2022;239(2):1–7.
33. Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. *J Autoimmun*. 2020;176(3):139–48.
34. Panikkath DR, Sandhu VK. Cutaneous manifestations of systemic lupus erythematosus. *J Dermatol Nurses Assoc*. 2022;14(4):163–9.
35. Selvaraja M, Abdullah M, Md Shah A, Arip M, Amin Nordin S. Systematic Lupus Erythematosus (SLE): A review on the prevalence, clinical manifestation, and disease assessment. *Prog Microbes Mol Biol*. 2020;3(1):1–8.
36. Quismorio FP Jr, Quismorio AV. Clinical application of serologic tests, serum protein abnormalities, and other clinical laboratory tests in systemic lupus erythematosus. In: *Dubois' Lupus Erythematosus and Related Syndromes*. Los Angeles: Elsevier; 2019.
37. Concha JSS, Werth VP. Alopecias in lupus erythematosus. *Lupus Sci Med*. 2018;5(1):1–10.

38. Kudsi M, Nahas LD, Alsawah R, Hamscho A, Omar A. The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients. *Arthritis Res Ther.* 2021;23(1):4–8.
39. Sarwar S, Mohamed AS, Rogers S, Sarmast ST, Kataria S, Mohamed KH, et al. Neuropsychiatric systemic lupus erythematosus: A 2021 update on diagnosis, management, and current challenges. *Cureus.* 2021;13(9):1–11.
40. Shin JI, Lee KH, Park S, Yang JW, Kim HJ, Song K, et al. Systemic lupus erythematosus and lung involvement: A comprehensive review. *J Clin Med.* 2022;11(22):1–23.
41. Kuhn A, Bonsmann G, Anders H-J, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. *Dtsch Arztebl Int.* 2015;112(25):423–32.
42. Admou B, Eddehbi F-E, Elmoumou L, Elmojadili S, Salami A, Oujidi M, et al. Anti-double stranded DNA antibodies: A rational diagnostic approach in limited-resource settings. *Pract Lab Med.* 2022;3(5):1–6.
43. Van Beers JJBC, Schreurs MWJ. Anti-Sm antibodies in the classification criteria of systemic lupus erythematosus. *J Transl Autoimmun.* 2022;5(3):1–6.
44. Arnaud L, Tektonidou MG. Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors. *Rheumatology (Oxford).* 2020;59(5):29–38.
45. Murray, Robert K., Daryl K. Granner, dan Victor W. Rodwell. *Biokimia Harper Edisi 27.* Jakarta: Penerbit Buku Kedokteran EGC; 2006.
46. Jia PW, Pan J, Zou YW, Zheng HW, Ma JD, Ouyang ZM, et al. Ab0319 high prevalence of hypoalbuminemia in patients with active rheumatoid arthritis. *Annals of the Rheumatic Diseases.* 2023;82(1):1343–43.
47. Peralta, R. Role of serum albumin in maintaining plasma oncotic pressure and fluid distribution. *J of Clin Invest.* 2019;127(3):807–12.
48. Kim S, McClave SA, Martindale RG, Miller KR, Hurt RT. Hypoalbuminemia and clinical outcomes: What is the mechanism behind the relationship?. *Am Surg.* 2017;83(11):1220–7.
49. Ramesh R, Suganthan N, Selvaratnam G, Anushanth U, Vijitharan V. Protein-losing enteropathy as the first presentation of systemic lupus erythematosus in a resource-limited setting in Sri Lanka: A case report. *Cureus.* 2023;15(3):1–5.
50. Nozaki Y. The network of inflammatory mechanisms in lupus nephritis. *Front Med (Lausanne).* 2020;7(11):1–9.
51. Poci-Gerardino G, Correa-Rodríguez M, Callejas-Rubio JL, Ríos-Fernández R, Ortego-Centeno N, Rueda-Medina B. Dietary intake and nutritional status



- in patients with systemic lupus erythematosus. *Endocrinol Diabetes Nutr.* 2018;65(9):533–9.
52. Yip J, Aghdassi E, Su J, Lou W, Reich H, Bargman J, et al. Serum albumin as a marker for disease activity in patients with systemic lupus erythematosus. *J Rheumatol.* 2010;37(8):1667–72.
53. Riyanto S, Hatmawan AA. Metode riset penelitian kuantitatif penelitian di bidang manajemen, teknik, pendidikan dan eksperimen. Yogyakarta: Deepublish; 2020.
54. Andru G, Widhani A, Putranto R, Mansjoer A, Shatri H. Faktor-faktor yang berhubungan dengan kualitas tidur pasien faktor-faktor yang berhubungan dengan kualitas tidur pasien dengan lupus eritematosus sistemik sleep quality among patients with systemic lupus. *JPDI.* 2024;11(2):63–70.
55. Islami AA, Jafar FI, Kuncoro H. Evaluasi ketepatan penggunaan obat pada pasien lupus eritematosus sistemik (LES) di RSUD Kanujoso Djatiwibowo Kota Balikpapan Tahun 2020-2021. *Proceeding Mulawarman Pharm Conf.* 2019;(4):135–8.
56. Hidayati I, Mirfat. Pola dermatoglifi pada tangan pasien lupus eritematosus sistemik di Yayasan Lupus Indonesia di Rumah Sakit Kramat 128 Jakarta Pusat. *Jr Med J.* 2023;2(1):133–42.
57. Esfandiari F, Pratama SA, Panonsih RN, Roselen RE. Hubungan faktor usia dengan kelelahan pada pasien systemic lupus erythematosus (SLE) di komunitas Lampung tahun 2019. *Jr Med M.* 2020;4(4):249–56.
58. Nabila D, Monalisa, Ekaputri TW. Hubungan tingkat aktivitas penyakit dengan kejadian depresi pada pasien systemic lupus erythematosus (SLE) di poliklinik penyakit dalam RSUD Raden Mattaher Jambi periode juli 2023 – Oktober 2023. [Skripsi]. [Jambi]: Universitas Jambi; 2023.
59. Intawang K, Sari IY. Hubungan dukungan keluarga dengan tingkat kecemasan pada pasien sistemic lupus erythematosus di poliklinik reumatologi RSU ST Elisabeth Purwokerto. [Skripsi]. [Yogyakarta]: Stikes Bethesda Yakum Yogyakarta; 2023.
60. Army S, Ladyani F, Esfandiari F, Kriswiastiny. Hubungan derajat aktivitas penyakit dengan fibromialgia pada pasien systemic lupus erythematosus (SLE) di komunitas odapus lampung. *Jr Med M.* 2022;2(3):445–452.
61. Sachdeva R, Pal R. The influence of reproductive hormones on systemic lupus erythematosus. *Explor Immunol.* 2022;2(6):351–62.
62. Jones JM, Jørgensen TN. Androgen-mediated anti-inflammatory cellular processes as therapeutic targets in lupus. *Front Immunol.* 2020;11(6):1–7.

63. Tangtanatakul P, Lei Y, Jaiwan K, Yang W, Boonbangyang M, Kunhapan P, et al. Association of genetic variation on X chromosome with systemic lupus erythematosus in both Thai and Chinese populations. *Lupus Sci Med*. 2024;11(1):1–8.
64. Al-Mogairen SM. Lupus protein-losing enteropathy (LUPLE) : A systematic review. *Rheumatol Int*. 2011;31(2):995–1001.
65. Liu Q, Liu Y, Feng H, Zhao L, Wan T. Exploring genetic association in systemic lupus erythematosus through Mendelian randomization: implications for novel biomarkers and therapeutic targets. *Clin Rheumatol*. 2024;30(8):1–10.
66. Partan RU, Hermansyah H, Darma S, Reagan M, Muthia P, Salim EM, et al. Manifestasi klinis dan derajat aktivitas penyakit pada penyandang lupus eritematosus sistemik di Rumah Sakit Dr. Mohammad Hoesin Palembang. *J Pengabdian Masy Humanit Med*. 2024;5(1):17–29.
67. Nabila FS, Miro S, Effendi R. Hubungan tingkat aktivitas penyakit lupus eritematosus sistemik dengan derajat gangguan fungsi ginjal pada pasien lupus eritematosus sistemik. [Skripsi]. [Padang]: Universitas Andalas; 2023
68. Sebtelia D, Ladyani F, Kriswastiny R, Esfandiari F. Hubungan derajat aktivitas penyakit dengan status kesehatan pada pasien systemic lupus erythematosus (SLE) di Komunitas Odapus Lampung. *MAHESA Malahayati Heal Student J*. 2022;2(4):667–73.
69. Smitherman E, Chahine R, Beukelman T, Knight A, Rahman AKMF, Son MB, et al. Predictors of moderate/high disease activity in childhood-onset systemic lupus erythematosus. *Arthritis Rheumatol*. 2020;72(4):220–2.
70. Khoerrunisah A, Asrori A, Karneli K, Edyansyah E. Frekuensi proteinuria pada penderita lupus eritematosus sistemik (LES). *J Med Lab Sci*. 2021;1(2):32–7
71. Xu J, Zhang H, Che N, Wang. FAR in systemic lupus erythematosus: a potential biomarker of disease activity and lupus nephritis. *Clin Exp Med*. 2023;23(6):4779–85.
72. Domingues V, Levinson BA, Bornkamp N, Goldberg JD, Buyon J, Belmont HM. Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. *Lupus Sci Med*. 2018;5(7):1–6.
73. Ahn SS, Jung SM, Song JJ, Park YB, Lee SW. Prognostic nutritional index is correlated with systemic lupus erythematosus. *Lupus*. 2018;27(10):1697–705
74. Nguyen B, Piarulli D, Johnson J, Horwitz D. Changes in serum albumin levels correlate highly with severity and activity of SLE. *Arthritis Rheumatol*. 2015;67(10):2–3.

75. Zhou Y, Ling X, Guo W, Lu N, Shen X, Zhou J. Role of IL-6 in different types chronic liver disease: From inflammatory response to fibrogenesis and hepatocellular carcinoma. Elsevier. 2015;26(3):351–63.

